The objective was to use a priori scoring algorithm designed to assess violations and non-violations on PANSS items, to compare PANSS ratings for subjects who were responders and non-responders to placebo treatment during participation in a clinical trial.
About the Author
Dr. Mark Opler serves as Chief Research Officer, directing scientific research and development at MedAvante-ProPhase. Dr. Opler was the founder of ProPhase and served as its CEO and Chief Scientific Officer among other positions. He holds the titles of Adjunct Assistant Professor of Psychiatry at New York University and Assistant Professor of Clinical Neuroscience at Columbia University’s College of Physicians and Surgeons. His academic research focuses on the etiology, phenomenology, and treatment of serious and persistent mental disorders. He is also leading the development of the new upcoming edition of the PANSS Manual©.
Follow on Linkedin
More Content by Dr. Mark Opler, PhD, MPH | Chief Research Officer